Biofrontera AG (B8FK.DE)

2.9950 0.0000 (0.00%) At close: 05:36PM CEST

Biofrontera AG

Hemmelrather Weg 201
Leverkusen 51377
Germany
49 214 87632 0
https://www.biofrontera.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 97

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Pilar de la Huerta Martinez	CFO & Member of Executive Board	369k	N/A	1969
Mr. Ludwig M. Lutter	Member of the Executive Board	435.65k	N/A	1967
Mr. Alexander Richardson	Head of UK Sales Team	N/A	N/A	N/A
Dr. Matthias Naumann	Head of Sales & Marketing - Europe	N/A	N/A	N/A
Dr. Montserrat Foguet Ph.D.	Managing Director of Biofrontera UK Ltd.	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Corporate governance

Biofrontera AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.